NASDAQ: CELG       Celgene Corp
Last Price Today's Change   Day's Range   Trading Volume
108.24   +0.11 (0.10%)  107.27 - 108.59  191,230,586


Avg Volume (4 weeks):191,230,586
4 Weeks Range:107.27 - 108.59
4 Weeks Price Volatility (%):
52 Weeks Range:82.26 - 110.70
52 Weeks Price Volatility (%):
Average Price Target: 130.00
Price Target Upside/Downside: +21.76


No recent Headlines for this stock.

Business Background

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

  Be the first to like this.


3528  2165  321  2955 

Top 10 Active Counters
 CELG 108.24+0.11 
 NIO 4.17-0.49 
 AVP 5.60-0.05 
 ACHN 6.88+0.75 
 AABA 19.630.00 
 VIAB 24.22+0.75 
 CHK 0.539-0.019 
 AMD 49.43-0.92 
 ECA 3.79-0.25 
 F 8.915-0.085 
Partners & Brokers